Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cryptococcosis

M H White1, D Armstrong

  • 1Memorial Sloan-Kettering Cancer Center, New York, New York.

Infectious Disease Clinics of North America
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Cryptococcal disease, a severe fungal infection in AIDS patients, often presents as meningitis. Amphotericin B is the primary treatment, while fluconazole is recommended for lifelong suppression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mycobacterium haemophilum infections in bone marrow transplant recipients.

Transplantation·1995
Same author

Patients' views of priority setting in health care: an interview survey in one practice.

BMJ (Clinical research ed.)·1995
Same author

Direct observations of surgical wound infections at a comprehensive cancer center.

Archives of surgery (Chicago, Ill. : 1960)·1995
Same author

Treatment of opportunistic infections in AIDS.

Lancet (London, England)·1995
Same author

A corporate needs assessment for the purchase of district nursing: a qualitative approach.

Public health·1995
Same author

Crouzon and Apert syndromes: intracranial volume measurements before and after cranio-orbital reshaping in childhood.

Plastic and reconstructive surgery·1995
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Area of Science:

  • * Infectious Diseases
  • * Mycology
  • * Immunology

Background:

  • * Cryptococcal disease is a major life-threatening fungal infection in individuals with Acquired Immunodeficiency Syndrome (AIDS).
  • * The most frequent presentation, cryptococcal meningitis, is characterized by a slow onset, potentially delaying diagnosis and treatment.
  • * Current treatment guidelines recommend amphotericin B, often in combination with flucytosine, as the preferred initial therapy.

Purpose of the Study:

  • * To review the current understanding and management strategies for cryptococcal disease in patients with AIDS.
  • * To highlight the importance of timely diagnosis and appropriate therapeutic interventions.
  • * To discuss the role of different antifungal agents in both initial treatment and long-term suppression.

Main Methods:

Related Experiment Videos

  • * Review of clinical trial data and established treatment guidelines for cryptococcal disease.
  • * Analysis of therapeutic efficacy for various antifungal agents.
  • * Discussion of prognostic factors and preventive strategies.

Main Results:

  • * While fluconazole shows efficacy in some cases, amphotericin B (with or without flucytosine) remains the gold standard for initial treatment of cryptococcal disease.
  • * Lifelong suppressive therapy with fluconazole is crucial for preventing relapse after initial treatment.
  • * The development and application of prognostic staging systems can aid in patient management.
  • * Primary prophylaxis strategies are essential for high-risk populations.

Conclusions:

  • * Effective management of cryptococcal disease in AIDS patients requires a dual approach: aggressive initial therapy followed by lifelong suppressive treatment.
  • * Amphotericin B-based regimens are recommended for initial treatment, whereas fluconazole is optimal for long-term suppression.
  • * Prognostic staging and primary prophylaxis are vital components in reducing the morbidity and mortality associated with cryptococcal disease.